Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.64 |
| ▸ | HTT | P42858 | 2/20 | 0.62 |
| ▸ | NCF1 | P14598 | 1/20 | 0.58 |
| ▸ | HTR6 | P50406 | 1/20 | 0.56 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27920322 | 0.92 | HTR2C (0.54) | HTR2CHTTNCF1HTR6HRH4 | |
| SCHEMBL22715393 | 0.86 | HRH4 (0.45) | HTR2CHTTNCF1HTR6HRH4 | |
| SCHEMBL29439726 | 0.86 | HRH4 (0.45) | HTR2CHTTNCF1HTR6HRH4 | |
| SCHEMBL15206322 | 0.83 | PRKCH (0.46) | HTR2CHTTNCF1HTR6 | |
| SCHEMBL3676460 | 0.82 | HTR2C (0.64) | HTR2CNCF1HTR6HRH4 | |
| SCHEMBL13170117 | 0.82 | HTR2C (0.64) | HTR2CHTTHTR6HRH4EPHX2 | |
| SCHEMBL3683503 | 0.82 | HRH4 (0.64) | HTTHRH4 | |
| SCHEMBL3680498 | 0.82 | HTR6 (0.66) | HTR2CHTR6HRH4 | |
| SCHEMBL3679652 | 0.82 | HTR2C (0.64) | HTR2CHTR6HRH4EPHX2 | |
| Hydrochloric Acid SCHEMBL3677880 | 0.81 | HTR2C (0.62) | HTR2CHTTHTR6HRH4EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7799775-B2 | such as 3-amino-5,6-dimethyl-2-[3-(4-quinolin-2-ylpiperazin-1-yl)propylthio]-3H-thieno[2,3-d]pyrimidin-4-one, having serotonin receptor modulatory activity, used for treating irritable bowel syndrome | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2010-09-21 | — | — | US | claimed |
| EP-1724267-B1 | PYRIMIDINE DERIVATIVE | ASKA PHARM CO LTD (JP) | 2013-11-06 | — | — | EP | disclosed |
| EP-1724267-B1 | PYRIMIDINE DERIVATIVE | ASKA PHARM CO LTD (JP) | 2013-11-06 | — | — | EP | disclosed |
| US-7799775-B2 | such as 3-amino-5,6-dimethyl-2-[3-(4-quinolin-2-ylpiperazin-1-yl)propylthio]-3H-thieno[2,3-d]pyrimidin-4-one, having serotonin receptor modulatory activity, used for treating irritable bowel syndrome | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2010-09-21 | — | — | US | disclosed |
| US-7799775-B2 | such as 3-amino-5,6-dimethyl-2-[3-(4-quinolin-2-ylpiperazin-1-yl)propylthio]-3H-thieno[2,3-d]pyrimidin-4-one, having serotonin receptor modulatory activity, used for treating irritable bowel syndrome | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2010-09-21 | — | — | US | disclosed |
| US-7799775-B2 | such as 3-amino-5,6-dimethyl-2-[3-(4-quinolin-2-ylpiperazin-1-yl)propylthio]-3H-thieno[2,3-d]pyrimidin-4-one, having serotonin receptor modulatory activity, used for treating irritable bowel syndrome | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2010-09-21 | — | — | US | disclosed |
| US-20070197551-A1 | Pyrimidine derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-23 | — | — | US | disclosed |
| US-20070197551-A1 | Pyrimidine derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-23 | — | — | US | disclosed |
| US-20070197551-A1 | Pyrimidine derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-23 | — | — | US | disclosed |
| EP-1724267-A1 | PYRIMIDINE DERIVATIVE | ASKA Pharmaceutical Co., Ltd. (JP) | 2006-11-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197551-A1 | Pyrimidine derivatives | HTR3B, HTR3A, HTR1A | HTR2C 14/4885HTT 1924/4885NCF1 1250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.